KAT2B
MOLECULAR TARGETlysine acetyltransferase 2B
KAT2B (lysine acetyltransferase 2B) is targeted by 10 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting KAT2B
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | epigalocatechin gallate | 5.40 | 220 |
| 2 | embelin | 3.26 | 25 |
| 3 | anacardic acid | 3.09 | 21 |
| 4 | gsk046 | 2.40 | 10 |
| 5 | gsk620 | 2.30 | 9 |
| 6 | garcinol | 2.20 | 8 |
| 7 | np1 | 2.08 | 7 |
| 8 | gsk778 | 2.08 | 7 |
| 9 | egcg | 0.69 | 1 |
| 10 | plumbagin [Supplementary Concept] | 0.69 | 1 |
About KAT2B as a Drug Target
KAT2B (lysine acetyltransferase 2B) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 10 compounds with documented KAT2B interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
KAT2B inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.